Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04050410 · ClinicalTrials.gov registry record · Early Phase 1

Autonomic Determinants of POTS - Pilot1

A Early Phase 1 study of Postural Tachycardia Syndrome, sponsored by Vanderbilt University Medical Center.

Active
Registry status
Early Phase 1
Development phase
48
Enrollment target
1
Study location

NCT04050410 is a Early Phase 1 study of Postural Tachycardia Syndrome that is active but no longer recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 48 participants, below the 80-participant average among 19 other Postural Tachycardia Syndrome trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04050410, a Early Phase 1 study of Postural Tachycardia Syndrome, is active but no longer recruiting, sponsored by Vanderbilt University Medical Center.

ACTIVE NOT RECRUITING
Registry status
Early Phase 1
Development phase
48 participants
Enrollment target
1
Study location

Study Summary

Postural tachycardia syndrome (POTS) is a relatively common condition affecting mostly otherwise healthy young women. It is the cause of significant disability and an impairment in quality of life. These patients have high heart rate and symptoms during standing. Many of these patients are disabled and have a poor quality of life. The sympathetic nerves are part of the nervous system that helps to maintain normal blood pressures and heart rates during activities of daily life. The purpose of this study is to determine the importance of sympathetic activation as a cause of orthostatic symptoms. The investigators will assess the effects of a blood pressure medication (Moxonidine) on the symptoms during standing. Moxonidine lowers sympathetic activity. The investigators believe patients with high resting sympathetic activity might benefit from Moxonidine. It might reduce high heart rate and improve symptoms during standing. This study should help clinicians and the growing population of patients with POTS gain a better understanding of this disorder and find more personalized treatment.

Conditions Studied

Postural Tachycardia Syndrome

Interventions

  • DRUG Placebo
  • DRUG Moxonidine

Study Locations (1)

Tennessee

  • Vanderbilt University Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2019-08-27
Est. Completion 2025-12-31
Phase Early Phase 1

Sponsor

Vanderbilt University Medical Center

677 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04050410

The ClinicalTrials.gov registry entry for NCT04050410 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 80-participant average among 19 other Postural Tachycardia Syndrome trials with a reported enrollment target (40% lower). The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Postural Tachycardia Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04050410 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.

Frequently Asked Questions

What is clinical trial NCT04050410 about?

NCT04050410 is a clinical study titled "Autonomic Determinants of POTS - Pilot1". Postural tachycardia syndrome (POTS) is a relatively common condition affecting mostly otherwise healthy young women. It is the cause of significant disability and an impairment in quality of life. These patients have high heart rate and symptoms during standing. Many of these patients are disabled ...

What is the current status of trial NCT04050410?

This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 48 participants. The study started on 2019-08-27. Estimated completion is 2025-12-31.

What conditions does trial NCT04050410 study?

This clinical trial studies the following conditions: Postural Tachycardia Syndrome.

What interventions are being tested in trial NCT04050410?

The interventions under investigation include: Placebo (DRUG), Moxonidine (DRUG).

Who is sponsoring clinical trial NCT04050410?

This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04050410 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Postural Tachycardia Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Postural Tachycardia Syndrome

All registered trials for this condition

Tennessee

All trials with a study site in Tennessee

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.